Nordwand Advisors LLC Buys 1,514,824 Shares of NovoCure Limited (NASDAQ:NVCR)

Nordwand Advisors LLC boosted its holdings in NovoCure Limited (NASDAQ:NVCR - Free Report) by 100.0% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,029,824 shares of the medical equipment provider's stock after buying an additional 1,514,824 shares during the period. NovoCure makes up 12.7% of Nordwand Advisors LLC's investment portfolio, making the stock its 3rd biggest holding. Nordwand Advisors LLC owned approximately 2.80% of NovoCure worth $47,356,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Ridgewood Investments LLC bought a new position in shares of NovoCure during the second quarter valued at about $28,000. Signaturefd LLC raised its position in NovoCure by 61.7% in the second quarter. Signaturefd LLC now owns 1,644 shares of the medical equipment provider's stock worth $28,000 after acquiring an additional 627 shares during the period. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of NovoCure in the second quarter worth $34,000. Fifth Third Bancorp bought a new stake in NovoCure in the 2nd quarter valued at $43,000. Finally, Nisa Investment Advisors LLC bought a new stake in NovoCure in the 2nd quarter valued at $48,000. 84.61% of the stock is currently owned by hedge funds and other institutional investors.

NovoCure Trading Down 1.2 %

NVCR traded down $0.21 on Friday, reaching $17.44. 1,171,937 shares of the company's stock were exchanged, compared to its average volume of 1,383,922. The company's 50 day moving average is $16.58 and its 200-day moving average is $18.06. The company has a market cap of $1.89 billion, a price-to-earnings ratio of -12.46 and a beta of 0.71. NovoCure Limited has a twelve month low of $10.87 and a twelve month high of $24.74. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.44 and a current ratio of 1.49.

NovoCure (NASDAQ:NVCR - Get Free Report) last announced its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.06. NovoCure had a negative return on equity of 41.48% and a negative net margin of 25.93%. The firm had revenue of $155.10 million for the quarter, compared to analysts' expectations of $143.95 million. During the same period last year, the business posted ($0.46) earnings per share. The firm's revenue for the quarter was up 21.8% on a year-over-year basis. Equities analysts predict that NovoCure Limited will post -1.31 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts recently commented on NVCR shares. HC Wainwright reaffirmed a "buy" rating and set a $30.00 price target on shares of NovoCure in a research note on Thursday, October 31st. Wedbush reaffirmed an "outperform" rating and issued a $24.00 price objective on shares of NovoCure in a report on Thursday, July 25th. Wells Fargo & Company lowered their price target on shares of NovoCure from $42.00 to $40.00 and set an "overweight" rating on the stock in a report on Friday, July 26th. Finally, Evercore ISI reduced their target price on shares of NovoCure from $21.00 to $18.00 and set an "in-line" rating for the company in a research report on Tuesday, October 1st. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat, NovoCure has a consensus rating of "Moderate Buy" and a consensus price target of $26.17.

NovoCure Company Profile

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua.